title: [Blood pressure control in hypertensive patients with stable coronary heart disease].
abstract: OBJECTIVE
  To evaluate systolic blood pressure (SBP) control in hypertensive patients with a stable coronary heart disease (CHD) in general practice in France.
  
  
  METHODS
  A survey was conducted in a sample of 206 general practitionners (GP) representative of the French medical population, in 2003 [LHYCORNE survey]. Each GP had to include 3 hypertensive patients, >18 years old, BP > or = 140/90 mmHg and/or treated for hypertension, and with evidence of CHD documented by myocardial infarction (MI) or angina pectoris (AP) [diagnosis previously established by a cardiologist]. Three office BP measurements were performed, the last two recorded. BP levels were considered as controlled by treatement if they were < 140/90 mmHg.
  
  
  RESULTS
  595 patients were included, 75% men mean age 66 years, 25% women mean age 73 years. All patients had a CHD: MI 46%, AP 54%; 533 (90%) had more than 2 cardiovascular risk factors: hyperlipidemia (411; 69%), smokers (375; 63%), diabetes (158; 27%). Mean BP was 140.7 +/- 14/80.8 +/- 9.7 mmHg; 553 (93%) of these hypertensive patients were treated, and 239 (40%) were considered as having a controlled SBP at the treshold of 140 mmHg: 47% in patients with previous MI and 38% with AP (p < 0.001). Diastolic BP (DBP) was <90 mmHg in 480 (81%) and pulse pressure was >65 mmHg in 202 (34%); 313 (53%) patients received a combination of three drugs or more; 354 (60%) had a beta-blocker, 260 (44%) a calcium channel blocker, 237 (40%) an ACE inhibitor, 287 (48%) other antihypertensive drugs (246 diuretics, 41%); 502 (84%) received antiplatelet therapy, 403 (68%) statins.
  
  
  CONCLUSIONS
  This survey shows that systolic BP is not at goal in 6/10 hypertensive patients with stable CHD suggesting there is a place for a more effective combination therapy according to evidence-based medicine.
authors.affiliation: Service de médecine interne, HTA, CHU Rangueil, Toulouse.
authors.forename: B
authors.initials: B
authors.lastname: Chamontin
authors.forename: J
authors.initials: J
authors.lastname: Beaune
authors.forename: J P
authors.initials: JP
authors.lastname: Cambou
authors.forename: B
authors.initials: B
authors.lastname: Vaisse
authors.forename: G
authors.initials: G
authors.lastname: Bonnelye
authors.forename: S
authors.initials: S
authors.lastname: Ricard
authors.forename: L
authors.initials: L
authors.lastname: Josse
authors.forename: H
authors.initials: H
authors.lastname: Gallois
mesh_terms: D000328:Adult; D000368:Aged; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D003327:Coronary Disease / Q000150:complications*; D005260:Female; D005602:France; D006306:Health Surveys; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D000959:Antihypertensive Agents